HTG Molecular Diagnostics (HTG Molecular Diagnostics) Cash per Share : $2.96 (As of Mar. 2023)

View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). HTG Molecular Diagnostics's Cash per Share for the quarter that ended in Mar. 2023 was $2.96.

HTG Molecular Diagnostics Cash per Share Historical Data

The historical data trend for HTG Molecular Diagnostics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Cash per Share Chart

HTG Molecular Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash per Share

Get a 7-Day Free Trial

195.92

102.35

66.22

34.70

5.52

HTG Molecular Diagnostics Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash per Share	Get a 7-Day Free Trial															30.15	15.32	7.09	5.52	2.96

HTG Molecular Diagnostics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

HTG Molecular Diagnostics's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	12.211	/	2.21
	=	5.52

HTG Molecular Diagnostics's Cash per Share for the quarter that ended in Mar. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	6.563	/	2.21
	=	2.96

HTG Molecular Diagnostics (OTCPK:HTGMQ) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

HTG Molecular Diagnostics Cash per Share Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3430 E. Global Loop, Tucson, AZ, USA, 85706

Website

https://www.htgmolecular.com

HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.

Executives

Stephen Barat	officer: Senior VP of Therapeutics	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc.	10 percent owner	1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy	director
Byron Lawson	officer: SVP/Chief Commercial Officer	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson	director, officer: President & CEO
Laurence W Lytton	10 percent owner	467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski	officer: VP of Accounting and Reporting	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans	officer: VP, Finance & Admin. & CFO	3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen	10 percent owner	HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison	director